Profile data is unavailable for this security.
About the company
ispace Inc is primarily engaged in lunar development business. The Company provides payload services, data services, and partnership services using its own landers and rovers. In the payload service, the Company loads the customer's cargo, which is the goods to be transported to the moon, onto the Group's landers and rovers, and provide transportation to the moon. In addition to direct data collection, the data service confirms the customer's need to collect data using the Company's payloads, send the results back to earth as data, analyze them, and utilize them in the next stage of research and development (R&D). The partnership service is a partnership program in which the Company sells a package that includes rights to use the Company group's activities as content, exposure of its logo in advertising media, and data usage rights, and collaborates in technological and business development.
- Revenue in JPY (TTM)1.99bn
- Net income in JPY-2.52bn
- Incorporated2010
- Employees216.00
- Locationispace Inc2-7-17, ShibaCHUO-KU 103-0007JapanJPN
- Phone+81 362776451
- Websitehttps://ispace-inc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daito Pharmaceutical Co Ltd | 45.19bn | 3.28bn | 39.28bn | 1.01k | 12.04 | 0.7555 | 5.78 | 0.8691 | 207.85 | 207.85 | 2,864.81 | 3,311.81 | 0.6193 | 1.81 | 2.65 | 44,701,280.00 | 4.35 | 6.99 | 5.64 | 9.29 | 21.38 | 22.71 | 7.03 | 8.83 | 1.15 | -- | 0.1231 | 17.08 | 3.77 | 2.49 | -22.88 | 3.43 | 7.48 | 12.70 |
| Fuji Pharma Co Ltd | 41.64bn | 5.06bn | 39.63bn | 1.62k | 7.69 | 0.9272 | 4.82 | 0.9518 | 208.19 | 208.19 | 1,713.27 | 1,726.70 | 0.5039 | 1.40 | 2.82 | 25,687,230.00 | 6.12 | 4.10 | 8.90 | 5.58 | 38.51 | 42.41 | 12.15 | 7.55 | 0.7165 | -- | 0.3947 | 31.17 | 15.42 | 1.52 | 27.41 | 0.3709 | 19.04 | 5.73 |
| Seikagaku Corp | 34.68bn | 1.31bn | 42.10bn | 976.00 | 30.87 | 0.5637 | 14.55 | 1.21 | 24.00 | 24.00 | 635.69 | 1,314.47 | 0.4431 | 1.75 | 4.31 | 35,530,740.00 | 1.67 | 0.438 | 1.80 | 0.4797 | 50.52 | 55.91 | 3.77 | 1.07 | 5.44 | -- | 0.0055 | 452.20 | -4.00 | 2.09 | -40.10 | -10.63 | 8.40 | 0.00 |
| Shin Nippon Biomedical Laboratories Ltd | 26.70bn | 5.50bn | 63.91bn | 1.21k | 11.61 | 2.12 | 8.77 | 2.39 | 132.18 | 132.18 | 641.45 | 725.03 | 0.4107 | 1.27 | 5.55 | 22,105,960.00 | 8.46 | 9.47 | 12.30 | 14.34 | 52.19 | 50.00 | 20.60 | 24.39 | 0.9618 | -- | 0.4687 | 23.01 | 41.37 | 8.61 | -14.98 | -- | 37.23 | -- |
| Katakura Industries Co., Ltd. | 39.97bn | 3.05bn | 66.03bn | 1.04k | 20.41 | 0.8283 | 11.21 | 1.65 | 91.86 | 91.86 | 1,206.19 | 2,263.56 | 0.2879 | 2.26 | 4.70 | 38,434,620.00 | 2.33 | 2.35 | 3.05 | 3.34 | 38.45 | 37.75 | 8.09 | 8.32 | 2.57 | -- | 0.1236 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
| ASKA Pharmaceutical Holdings Co Ltd | 62.03bn | 6.51bn | 69.29bn | 747.00 | 9.85 | 1.06 | 7.36 | 1.12 | 230.05 | 230.05 | 2,191.75 | 2,131.76 | 0.6682 | 1.72 | 3.40 | 83,033,460.00 | 7.02 | 3.37 | 9.09 | 4.25 | 48.12 | 45.39 | 10.50 | 5.02 | 1.96 | -- | 0.1433 | 15.79 | 6.81 | 4.32 | -1.21 | 12.16 | -13.15 | 2.71 |
| ispace Inc | 1.99bn | -2.52bn | 70.78bn | 216.00 | -- | 17.06 | -- | 35.54 | -33.88 | -33.88 | 24.76 | 44.55 | 0.1476 | -- | 24.87 | 9,219,852.00 | -18.66 | -- | -32.11 | -- | 46.91 | -- | -126.42 | -- | 1.72 | -16.56 | 0.7317 | -- | 46.74 | -- | -180.75 | -- | -- | -- |
| Eiken Chemical Co Ltd | 39.90bn | 2.95bn | 78.12bn | 754.00 | 25.71 | 1.50 | 14.91 | 1.96 | 78.83 | 78.83 | 1,067.99 | 1,355.09 | 0.6013 | 2.74 | 3.07 | 52,923,080.00 | 4.44 | 8.83 | 5.45 | 11.34 | 42.67 | 46.39 | 7.38 | 12.16 | 2.95 | -- | 0.0563 | 31.24 | 0.6396 | 4.34 | -7.75 | 17.07 | 0.6216 | 15.33 |
| JCR Pharmaceuticals Co Ltd | 41.37bn | 5.36bn | 104.53bn | 879.00 | 18.84 | 1.81 | 12.76 | 2.53 | 42.78 | 42.78 | 330.47 | 445.94 | 0.4253 | 0.5492 | 3.03 | 47,059,160.00 | 5.53 | 9.63 | 8.38 | 14.67 | 74.83 | 74.34 | 12.99 | 19.32 | 1.15 | 19.24 | 0.294 | 27.35 | -32.77 | 10.77 | -74.00 | 4.20 | 53.67 | 25.21 |
Data as of May 02 2024. Currency figures normalised to ispace Inc's reporting currency: Japanese Yen JPY
2.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Asset Management One Co., Ltd.as of 15 May 2023 | 1.14m | 1.23% |
| Simplex Asset Management Co., Ltd.as of 04 Apr 2024 | 394.50k | 0.42% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 143.60k | 0.15% |
| Penserra Capital Management LLCas of 04 Apr 2024 | 119.45k | 0.13% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 50.60k | 0.05% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 24.40k | 0.03% |
| TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 16.90k | 0.02% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 10.00k | 0.01% |
| Vanguard Investments Australia Ltd.as of 31 Mar 2024 | 7.30k | 0.01% |
| Geode Capital Management LLCas of 31 Jan 2024 | 6.60k | 0.01% |
More ▼
Data from 31 Dec 2023 - 19 Apr 2024Source: FactSet Research Systems Inc.
